Reports
Sale
Global Secondary Myelofibrosis Therapeutics Market Size, Share, Trends, Research: By Type: Targeted Therapy, Chemotherapy, Radiation Therapy; By Diagnosis: Physical Tests, Imaging Tests, Blood Tests; By Drug Class: Ruxolitnab, Fedratinib, Pomalidomide; Regional Analysis; Patent Analysis; Grants Analysis; Supplier Landscape; 2024-2032
Global Secondary Myelofibrosis Therapeutics Market Outlook
The global secondary myelofibrosis therapeutics market size was valued at USD 2.03 billion in 2023, driven by the rising number of cancer and developing new therapies across the globe. The market size is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032 to achieve a value of USD 3.70 billion by 2032.
Secondary Myelofibrosis Therapeutics: Introduction
Myelofibrosis is a rare type of blood cancer where bone marrow (the soft, spongy tissue inside of your bones) is replaced by fibrous scar tissue. It is a form of chronic leukemia and a myeloproliferative disorder. Myeloproliferative disorders involve too many blood cells getting made in bone marrow- where blood cells get made.
Bone marrow produces immature blood-forming cells called stem cells that may develop into red blood cells, white blood cells or platelets. With myelofibrosis, a change (mutation) in a stem cell’s DNA causes the cell to become defective, or a cancer cell, instead. The cell multiplies, passing the mutation onto new cells. There are two types of myelofibrosis:
- Primary myelofibrosis is myelofibrosis that occurs on its own.
- Secondary myelofibrosis arises secondary to other blood disorders, including primary thrombocytosis or polycythemia vera. Secondary myelofibrosis accounts for about 10% to 20% of diagnoses.
Secondary myelofibrosis, also known as secondary myelofibrosis or secondary myeloid metaplasia, takes place when the bone marrow undergoes alterations that lead to the abnormal accumulation of fibrous tissue. Symptoms of secondary myelofibrosis could include fatigue, fever, itching, pale skin, weight loss, night sweats, bone, or joint pain among others. It can also be diagnosed with several approaches such as blood tests and bone marrow tests with some other diagnosis as well. Such as imaging procedures, gene mutation analysis.
Global Secondary Myelofibrosis Therapeutics Market Analysis
The continuous technological advancement and development of new therapies are the key factors driving the market growth. The increasing investments by key players and government in research and development of new therapies are also driving the market growth. Disorders that involve the overproduction of certain blood cell types leading to changes in the bone marrow such as polycythemia vera, essential thrombocythemia. The increasing emphasis on research and development of new treatments to overcome the condition in patients is a major trend influencing the global secondary myelofibrosis therapeutics market expansion. To overcome the issues associated with early JAK inhibitors (ruxolitinib and fedratinib), such as limited tolerability, pacritinib has been developed and recently approved for patients with thrombocytopenia, while momelotinib is in development for those with anemia. Pacritinib is an anti-cancer medication used to treat myelofibrosis and momelotinib is an inhibitor of Janus kina.
The key players are also continuously putting efforts towards developing the most effective drug and the rising approvals, which is likely to add further value to the global secondary myelofibrosis therapeutics market share. For example, Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, made it public about the Fast Track Designation grant put in action by the United States Food and Drug Administration (FDA) to the development program of Selinexor. It will be used in the treatment of myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis.
Additionally, the rising number of clinical trials are also increasing the awareness and curiosity of healthcare providers and researchers to explore the best potential drug to treat secondary myelofibrosis, leading to the market growth. For instance- the results of a case study on SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials exhibited improvements in symptom score and spleen reduction. It also suggested a possible treatment for MF-related anemia. A decrease in overall transfusions and an increase in transfusion independence was witnessed in all three trials.
Global Secondary Myelofibrosis Therapeutics Market Segmentations
Market breakup Market by Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
Market breakup by Diagnosis
- Physical Tests
- Imaging Tests
- Blood Tests
Market breakup by Drug Class
- Ruxolitnab
- Fedratinib
- Pomalidomide
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Secondary Myelofibrosis Therapeutics Market Overview
The increasing prevalence of cancer is also a major factor contributing to the market growth as cancer treatments, such as chemotherapy and radiation therapy, can damage bone marrow cells, which eventually may result in the development of myelofibrosis. The increasing development of drugs and increasing awareness about combination therapies are also contributing to the global secondary myelofibrosis therapeutics market development such as multiple drugs are currently being developed and examined in clinical trials, both as standalone therapy and in combination with JAK inhibitors, with promising results increasing the benefits of JAK inhibitors in treatment of myelofibrosis.
The rising awareness about cancer treatments such as chemotherapy and radiotherapy are also driving the market growth. The increasing advancements in therapeutic treatment approaches for secondary myelofibrosis are further propelling the market growth. Along with above mentioned factors, large patient pool, increasing incidences of genetic disorders, rising habit of smoking are also continuously increasing the global secondary myelofibrosis therapeutics market growth.
Geographically, North America is expected to lead the regional market due to the rising prevalence of secondary myelofibrosis, rising advancements. Ongoing research and development activities along with approval of JAK inhibitors by FDA due to its efficacy shown by the treatment is a major factor driving the market growth. The well-established healthcare system of North America is also expected to drive growth due to the presence of robust advanced technologies for the treatment.
Secondary Myelofibrosis Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Competition Deep Dive
- Incyte Corporation
- Bristol-Myers Squibb Company
- Amneal Pharmaceuticals, Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Actuate Therapeutics Inc.
- Imago Biosciences
- Galecto, Inc
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis |
|
| Breakup by Drug Class |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Secondary Myelofibrosis Therapeutics Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Global Secondary Myelofibrosis Therapeutics Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Global Secondary Myelofibrosis Therapeutics Epidemiology (2016-2031)
5.3 Europe Global Secondary Myelofibrosis Therapeutics Epidemiology (2016-2031)
5.4 Asia-Pacific Global Secondary Myelofibrosis Therapeutics Epidemiology (2016-2031)
5.5 Latin America Global Secondary Myelofibrosis Therapeutics Epidemiology (2016-2031)
5.6 Middle East & Africa Global Secondary Myelofibrosis Therapeutics Epidemiology (2016-2031)
6 Global Secondary Myelofibrosis Therapeutics Market Overview
6.1 Global Secondary Myelofibrosis Therapeutics Market Historical Value (2017-2023)
6.2 Global Secondary Myelofibrosis Therapeutics Market Forecast Value (2024-2032)
7 Global Secondary Myelofibrosis Therapeutics Market Landscape
7.1 Global Secondary Myelofibrosis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Secondary Myelofibrosis Therapeutics: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Applications
8 Global Secondary Myelofibrosis Therapeutics Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Secondary Myelofibrosis Therapeutics Market Segmentation
9.1 Global Secondary Myelofibrosis Therapeutics Market by Type
9.1.1 Market Overview
9.1.2 Targeted Therapy
9.1.3 Chemotherapy
9.1.4 Radiation Therapy
9.2 Global Secondary Myelofibrosis Therapeutics Market by Diagnosis
9.2.1 Market Overview
9.2.2 Physical Tests
9.2.3 Imaging Tests
9.2.4 Blood Tests
9.3 Global Secondary Myelofibrosis Therapeutics Market by Drug Class
9.3.1 Market Overview
9.3.2 Ruxolitnab
9.3.3 Fedratinib
9.3.4 Pomalidomide
9.4 Global Secondary Myelofibrosis Therapeutics Market by Region
9.4.1 Market Overview
9.4.2 North America
9.4.3 Europe
9.4.4 Asia Pacific
9.4.5 Latin America
9.4.6 Middle East and Africa
10 North America Secondary Myelofibrosis Therapeutics Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Secondary Myelofibrosis Therapeutics Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Secondary Myelofibrosis Therapeutics Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Secondary Myelofibrosis Therapeutics Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Secondary Myelofibrosis Therapeutics Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Competition Deep Dive
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.1.5 Certifications
20.2 Incyte Corporation
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.2.5 Certifications
20.3 Bristol-Myers Squibb Company
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.3.5 Certifications
20.4 Amneal Pharmaceuticals, Inc.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.4.5 Certifications
20.5 AbbVie Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.5.5 Certifications
20.6 GlaxoSmithKline plc
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.6.5 Certifications
20.7 Pfizer Inc.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.7.5 Certifications
20.7.6 Shenzhen
20.8 Actuate Therapeutics Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.8.5 Certifications
20.9 Imago Biosciences
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.9.5 Certifications
20.10 Galecto, Inc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
20.10.5 Certifications
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.03 billion in 2023, driven by the increasing cancer cases.
The market is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032, likely to reach a market value of USD 3.70 billion by 2032.
The advancing healthcare infrastructure and the rising presence of a large patient pool with increasing incidences of genetic disorders are major factors driving the market growth.
The rising number of clinical trials and increasing approvals for drugs are among major trends influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Therapies used to treat secondary myelofibrosis are targeted therapy, chemotherapy, and radiation therapy.
Secondary myelofibrosis can be diagnosed with the help of physical tests, imaging tests, and blood tests.
Drug class used in the market are Ruxolitnab, Fedratinib, and Pomalidomide.
Key players involved in the market are Competition Deep Dive, Bristol-Myers Squibb Company, Amneal Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., Actuate Therapeutics Inc., Imago Biosciences, Galecto, Inc., and Incyte Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER